Physiological characterization of human ovarian cancer cells in a rat model of intraperitoneal antineoplastic therapy

Journal of Applied Physiology

Volumn 97, Issue 4, 2004, Pages 1518-1526

  Flessner, Michael F ^a   Choi, Jaehwa ^a   He, Zhi ^a   Credit, Kimberly ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Convection; Diffusion; Ovarian carcinoma; OVCAR3; SKOV3; Transport

Indexed keywords

CARBON 14; IODINE 125; MANNITOL; TRASTUZUMAB;

ABDOMINAL WALL; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL; CANCER CHEMOTHERAPY; CELL DESTRUCTION; CONTROLLED STUDY; DRUG DIFFUSION; DRUG PENETRATION; DRUG TARGETING; DRUG TISSUE LEVEL; EXTRACELLULAR SPACE; FEMALE; FROZEN SECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; RAT; TISSUE PRESSURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; MANNITOL; METABOLIC CLEARANCE RATE; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; RATS; RATS, NUDE; TISSUE DISTRIBUTION;

EID: 4644233232     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00305.2004     Document Type: Article

References (36)

1. Agostino A, Robin F, Jais JP, Aggerbeck M, Vilde F, Blanc B, and Lecuru F. Peritoneal closure reduces port site metastases: results of an experiment in a rat ovarian cancer model. Surg Endosc 16: 289-291, 2002.
2. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, and DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955, 1996.
3. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, LoBuglio AF, and Meredith RF. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-C.C.49: a phase III study. Gynecol Oncol 65: 94-101, 1997.
4. Boucher Y, Baxter LT, and Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478-4484, 1990.
5. Boucher Y and Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52: 5110-5114, 1992.
6. Boucher Y, Kirkwood JM, Opacic D, Desantis M, and Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 51: 6691-6694,1991.
7. Fadnes HO, Reed RK, and Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 29: 176-189, 1985.
8. Flessner MF. Transport of Water-Soluble Solutes Between the Peritoneal Cavity, and Plasma in the Rat. Ann Arbor, MI: Univ. of Michigan, 1981.
9. Flessner MF. Osmotic barrier of the parietal peritoneum. Am J Physiol Renal Fluid Electrolyte Physiol 267: F861-F870, 1994.
10. Flessner MF. Small-solute transport across specific peritoneal tissue surfaces in the rat. J Am Soc Nephrol 7: 225-233, 1996.
11. Flessner MF and Dedrick RL. Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration, and intraperitoneal solution osmolality. Cancer Res 54: 4376-4384, 1994.
12. Flessner MF, Dedrick RL, and Schultz JS. A distributed model of peritoneal-plasma transport: theoretical consideratons. Am J Physiol Regul Integr Comp Physiol 246: R597-R607, 1984.
13. Flessner MF, Lofthouse J, and Zakaria ER. In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol Heart Circ Physiol 273: H2783-H2793, 1997.
14. Flessner MF and Schwab A. Pressure threshold for fluid loss from the peritoneal cavity. Am J Physiol Renal Fluid Electrolyte Physiol 270: F377-F390, 1996.
15. Gerlowski LE and Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31: 288-305, 1986.
16. Gershenson DM, Tortolero-Luna G, Malpica A, Baker VV, Whitaker L, Johnson E, and Mitchell MF. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gyencol Clin North Am 23: 475-543, 1996.
17. Gullino PM and Grantham FH. The vascular space of growing tumors. Cancer Res 24: 1727-1732, 1964.
18. Gullino PM, Grantham FH, and Smith SH. The interstitial water space of tumors. Cancer Res 25: 727-731, 1965.
19. Hasan J, Byers R, and Jayson GC. Intra-tumoral microvessel density in human solid tumors. Br J Cancer 86: 1566-1577, 2002.
20. Hornung R, Fehr MK, Monti-Frayne J, Krasieva TB, Tromberg BJ, Berns MW, and Tadir Y. Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model. Photochem Photobiol 70: 624-629, 1999.
21. Ito T, Griffin TW, Collins JA, and Brill AB. Intratumoral and whole-body distributions of C110 anti-carcinoembryonic antigen radioimmunotoxin (RIT) after intraperitoneal and intravenous injection: a quantitative autoradiographic study. Cancer Res 52: 1961-1967, 1996.
22. Kairemo KJ. Radioimmunotherapy of solid cancer: a review. Acta Oncol 35: 343-355, 1996.
23. 131I-labelled monoclonal antibody 323/A3 in experimental human ovarian cancer. Intl J Radiol Oncol Biol Phys 38: 419-428, 2004.
24. Lecuru F, Guilbaud N, Agostini A, Augereau C, Vilde F, and Taurelle R. Description of two new ovarian carcinoma models in nude rats suitable for laparoscopic experimentation. Surg Endosc 15: 1346-1352, 2001.
25. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, and Jain RK. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 52: 6553-6560, 1992.
26. Markman M. Intraperitoneal therapy of ovarian carcinoma. Semin Oncol 25: 356-360, 1998.
27. Ong GL and Mattes MJ. Penetration, and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res 49: 4264-4273, 1989.
28. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, and Young RC. Pharmacokinetics of adriamycin, and tissue penetration in murine ovarian cancer. Cancer Res 39: 3209-3214, 1979.
29. Padera TP, Kadambi A, diTomaso E, Carrelra CM, Brown EB, Boucher Y, Chol NC, Mithisen D, Wain J, Mark EJ, Munn LL, and Jain RK. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883-1887, 2002.
30. 111In- labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 55, Suppl 23: 5736S-5742S, 1995.
31. Roh HD, Boucher Y, Kalnicki S, Buchsbaum R, Bloomer WD, and Jain RK. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation exposure. Cancer Res 51: 6695-6698, 1991.
32. Rose GS, Tocco LM, Granger GA, DiSaia PJ, Hamilton TC, Santin AD, and Hiserodt JC. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 175: 593-599, 1996.
33. Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, and Wagner JG. The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage. Cancer Immunol Immunother 26: 187-201, 1988.
34. Wiig H, Reed RK, and Aukland K. Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to the wick-in-needle technique. Microvasc Res 21: 308-319, 1981.
35. Yuan F, Leunig M, Berk DA, and Jain RK. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma L.S174T using dorsal chamber in SCID mice. Microvasc Res 45: 269-289, 1993.
36. Zakaria ER, Lofthouse J, and Flessner MF. In vivo effects of hydrostatic pressure on interstitium of abdominal wall muscle. Am J Physiol Heart Circ Physiol 276: H517-H529, 1999.